Literature DB >> 2855294

Efficacies of four antifungal agents in experimental murine sporotrichosis.

V L Kan1, J E Bennett.   

Abstract

Four antifungal agents, amphotericin B, SDZ 89-485, itraconazole, and terbinafine, were tested for efficacy in a murine model of systemic sporotrichosis. Survival in the groups treated with amphotericin B, SDZ 89-485, and itraconazole was significantly better than that of control infected mice. However, these agents did not wholly protect the infected mice, as tail and paw lesions, whole-body radiographs, and positive cultures from survivors showed evidence of dissemination. Terbinafine-treated mice had the same or poorer survival as control infected mice, despite documented drug absorption.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2855294      PMCID: PMC175939          DOI: 10.1128/AAC.32.11.1619

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Five unusual cases of sporotrichosis from South Africa showing lesions in muscles, bones, and viscera.

Authors:  H I LURIE
Journal:  Br J Surg       Date:  1963-05       Impact factor: 6.939

2.  Bioassay for SF 86-327, a new antifungal agent.

Authors:  V L Kan; D K Henderson; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

3.  Clinical features of extracutaneous sporotrichosis.

Authors:  D E Wilson; J J Mann; J E Bennett; J P Utz
Journal:  Medicine (Baltimore)       Date:  1967-05       Impact factor: 1.889

4.  Local heat in the treatment of sporotrichosis.

Authors:  A Trejos; O Ramírez
Journal:  Mycopathol Mycol Appl       Date:  1966-10-04

Review 5.  Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models.

Authors:  J Van Cutsem; F Van Gerven; P A Janssen
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

6.  Itraconazole therapy in lymphangitic and cutaneous sporotrichosis.

Authors:  A Restrepo; J Robledo; I Gómez; A M Tabares; R Gutiérrez
Journal:  Arch Dermatol       Date:  1986-04

7.  A diffusion chamber technique for testing of antifungal drugs against Sporothrix schenckii in vivo.

Authors:  M Schaude; J G Meingassner
Journal:  J Med Vet Mycol       Date:  1986-08

8.  Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.

Authors:  W E Dismukes; A M Stamm; J R Graybill; P C Craven; D A Stevens; R L Stiller; G A Sarosi; G Medoff; C R Gregg; H A Gallis; B T Fields; R L Marier; T A Kerkering; L G Kaplowitz; G Cloud; C Bowles; S Shadomy
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

9.  Antifungal activity of the allylamine derivative terbinafine in vitro.

Authors:  G Petranyi; J G Meingassner; H Mieth
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

10.  In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis.

Authors:  D M Dixon; A Polak
Journal:  Chemotherapy       Date:  1987       Impact factor: 2.544

View more
  13 in total

1.  In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine.

Authors:  Lidiane Meire Kohler; Paulo César Fialho Monteiro; Rosane Christine Hahn; Júnia Soares Hamdan
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

2.  Use of a mouse model to evaluate clinical and environmental isolates of Sporothrix spp. from the largest U.S. epidemic of sporotrichosis.

Authors:  D M Dixon; R A Duncan; N J Hurd
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

3.  Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.

Authors:  Enrique Calvo; F Javier Pastor; Emilio Mayayo; Pilar Hernández; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

4.  Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia.

Authors:  Peter D Walzer; Alan Ashbaugh
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.

Authors:  S Gupta; J Kim; S Gollapudi
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

6.  Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease.

Authors:  R A Maldonado; J Molina; G Payares; J A Urbina
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 7.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Authors:  J A Balfour; D Faulds
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

8.  In vitro antifungal susceptibilities of five species of sporothrix.

Authors:  Rita Marimon; Carolina Serena; Josepa Gené; Josep Cano; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

9.  Comparison of fluconazole and SDZ89-485 for therapy of experimental murine coccidioidomycosis.

Authors:  J Fierer; T Kirkland; F Finley
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

10.  Efficacy of posaconazole in murine experimental sporotrichosis.

Authors:  Fabiola Fernández-Silva; Javier Capilla; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.